Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation

Fig. 3

Effects of PDK2 knockdown on the migration of ovarian cancer cells. Both A2780 and A2780cp cells were transfected with PDK2 shRNA or scramble shRNA and then treated with 5 μg/ml cisplatin for 24 h. Representative microscopy images and cell numbers of A2780 (A, C) and A2780cp (B, D) cells. **P < 0.01, *P < 0.05

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us